Meet Rick

As an army doctor, cardiac surgeon, and lead guitarist, Rick served his country and fellow man, understanding the importance of trusting teams. See why he trusted his Heart Valve Team and TAVR by Edwards to fix his severe symptomatic aortic stenosis (heart valve failure).

YOUR CHOICE OF VALVE MATTERS

Not all TAVR (transcatheter aortic valve replacement) valves are the same

The SAPIEN 3 Ultra RESILIA valve is the latest valve approved in the SAPIEN 3 TAVR family of valves.

The SAPIEN 3 Ultra RESILIA valve is the latest valve approved in the SAPIEN 3 TAVR family of valves

Over a decade of success:
There are over 1 million TAVR patients worldwide

By receiving an Edwards SAPIEN transcatheter heart valve, you are getting one of the most widely used TAVR valves in the world.*

The SAPIEN 3 Ultra RESILIA valve is made of cow heart tissue that uses advanced technology to block the buildup of calcium. This RESILIA tissue treatment could potentially allow the valve to last longer.†1

GETTING TAVR? ASK FOR THE
EDWARDS SAPIEN 3 ULTRA RESILIA VALVE

The type of TAVR valve you receive can impact your heart and your future

Icon representing functioning heart

Designed like your heart

  • The TAVR valve is designed to work just like the one inside your body and begins to work immediately once implanted
Icon of checkmark inside of a shield

Designed to last

  • The frame of the valves is made from specialized materials for strength and durability
  • Edwards TAVR has better outcomes than open heart surgery in low-risk patients at 1 year—and has proven equally effective at 5 years‡2,3
Icon of person with stars next to their head

Designed for your unique needs

  • SAPIEN 3 TAVR valves are not one size fits all. They come in 4 sizes to meet the individual needs of each patient
Icon of two hands holding up a heart

Designed for your future

  • If you're like many patients with coronary artery disease, an Edwards TAVR valve means your physicians may have better access to your coronary arteries, should you ever need another procedure4,5

As with any medical procedure, there is a possibility of risks. The most serious risks of TAVR include death, stroke, serious damage to the arteries, or serious bleeding.

*Currently, does not include the SAPIEN 3 Ultra RESILIA valve.

RESILIA tissue has not been studied for long-term results in patients.

The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint of all-cause death, all stroke, and re-hospitalization (valve-related or procedure-related and including heart failure) at one year, and multiple pre-specified secondary endpoints in low risk patients.

PARTNER 3 Trial 5-Year Results in low-risk patients – Low rates of cardiovascular mortality through five years (5.5% SAPIEN 3 TAVR to 5.1% SAVR). Low rates of all-cause mortality through five years (10.1% SAPIEN 3 TAVR vs. 8.2% with SAVR). Low rates of disabling stroke through five years (2.9% SAPIEN 3 TAVR to 2.7% SAVR). Low rates of stroke through five years (5.8% SAPIEN 3 TAVR vs. 6.4% SAVR). Lower rates of rehospitalization with SAPIEN 3 TAVR through five years (13.7% vs. 17.4%).

Join Heart Valve Strong

Heart valve failure is serious. Having the right tools and resources will help you speak up and take action before things get worse.6,7

Register here
Icon of a finger pointing inside a heart

Get your TAVR Info Kit

Each kit is packed with valuable information and resources to help you better understand TAVR.

Get your kit
Icon of a checklist
References: 1.Flameng W, Hermans H, Verbeken E, Meuris B. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149:340-345. 2.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389(21):1949-1960. 3.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705. 4.Yudi MB, Sharma SK, Tang GHL, Kini A. Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;71(12):1360-1378. 5.De Backer O, Landes U, Fuchs A, et al. Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tomography. JACC Cardiovasc Interv. 2020;13(21):2528-2538. 6.Otto CM. Timing of aortic valve surgery. Heart. 2000;84(2):211-218. 7.Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72-e227.

Patients and/or clinicians quoted on this website have received compensation from Edwards Lifesciences.